linjc16/ctgov huggingface dataset:
Exercise Intervention on Frailty After Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
Researchers are trying to determine if exercise will improve health and strength in kidney transplant patients.

Official Title
-----------------
Examining the Preliminary Efficacy, Feasibility, and Acceptability of an Exercise Intervention on Frailty After Kidney Transplantation

Conditions
-----------------
Kidney Transplant

Intervention / Treatment
-----------------
* Other: Exercise Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age ≥ 18 years who have received a KT and have a functioning allograft Exclusion Criteria: Neuropsychiatric condition causing patient to be unable to provide consent Recipient of a combined organ transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Usual Care Group<br>Subjects will receive no formal exercise recommendations | |
| Experimental: Exercise Intervention Group<br>Subjects will complete an exercise program | Other: Exercise Program<br>* Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in frailty status | Frailty will be determined by Frailty Phenotype (FP) or Short Physical Performance Battery (SPPB) scores. FP is determined by the presence of 3 or more of the following: slowness (measured by gait speed), exhaustion (measured via self-report), weakness (measured by hand grip strength), low physical activity level (measured via self-report), and wasting (measured via self-report or by tracking changes in weight). The SPPB consists of a gait speed test, balance testing, and repeated chair stands. A score less than or equal to 10 will be considered frail. | Two months |
Inventory of Inappropriate Prescriptions of Proton Pump Inhibitors (PPIs) in People Over 75 Years of Age

Study Overview
=================
Brief Summary
-----------------
This study would have as a starting point the results of a request carried out by the Medical Service Grand Est of the Health Insurance aiming to evaluate the number of boxes of PPI reimbursed in town pharmacy, in patients over 75 years old in the Grand Est of France from 01/01/2018 to 31/12/2018. It aims to highlight and quantify a possible inappropriate use of PPIs in private practice.

Official Title
-----------------
Inventory of Inappropriate Prescriptions of Proton Pump Inhibitors (PPIs) in People Over 75 Years of Age When Taking Over a Patient Base in the SOULTZ Haut-Rhin Sector

Conditions
-----------------
Peptic Ulcer Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patient over 75 years of age Patient with a PPI in the initial prescription Patient seen at least once between 01/01/2018 and 31/11/2019 in the general practice Patient who has not expressed his opposition, after information, to the reuse of his data for the purpose of this research. Exclusion criteria: Patient having expressed his opposition to participate in the study Impossibility to give the patient informed information (difficulties in understanding the subject, ...) Patient under legal protection Patient under guardianship or curatorship Patient who is no longer followed up in the office following an entry into an institution (EHPAD)

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective systematic analysis of patient prescriptions to identify possible inappropriate use of PPIs in private practice |  | Files analysed retrospectively from January 01, 2018 to December 31, 2019 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PPI, Peptic Ulcer Disease, Proton pump inhibitors
Ultrasound Guided Embryo Transfer: Abdominal Versus Transvaginal, a RCT

Study Overview
=================
Brief Summary
-----------------
Ultrasound (US) guided embryo transfer (ET) appears to improve pregnancy outcomes in IVF-ET. Most reports are done using a transabdominal (TAS) approach, in contrast to a transvaginal ultrasound (TVS) which does not require a full bladder. We sought to determine if either approach was better with respect to clinical outcomes.

Official Title
-----------------
Abdominal Versus Transvaginal Ultrasound Guided Embryo Transfer: Results of a Randomized Clinical Trial

Conditions
-----------------
Infertility, in Vitro Fertilization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All patients undergoing assisted reproductive cycles including autologous IVF, oocyte donation, and frozen embryo transfer (FET) cycles Exclusion Criteria: - Cases of severe ovarian hyper-stimulation requiring embryo cryopreservation and gestational surrogate cycles
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>transabdominal ultrasound (TAS) guided embryo transfer | |
| 2<br>transvaginal ultrasound (TVS) guided embryo transfer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rates for TAS and TVS ultrasound-guided ET groups |  | August 2003 to June 2007 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of time required for embryo transfer |  | August 2003 to June 2007 | 
| differences between transferring physicians |  | August 2003 to June 2007 | 
| multiple pregnancies |  | August 2003 to June 2007 | 
| ectopic pregnancy rates |  | August 2003 to June 2007 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrasound-guided, embryo transfer, in-vitro fertilization
Intravenous Access Using Infrared Laser

Study Overview
=================
Brief Summary
-----------------
Peripheral venous access is a prerequisite for anesthesiological for surgical patients.It is often difficult to establish and potentially painful in obese patients (Body mass Index > 35). AV300 uses near infrared laser light to improve visibility of peripheral veins and could help cannulating them. The aim of this study was to examine if use of Accuvein(®) AV300 vein viewer could facilitate venous cannulation in obese patients (surgical and obstetric).

Official Title
-----------------
Peripheral Intravenous Cannulation With Support of Infrared Laser Vein Viewing System in Obese Patients

Conditions
-----------------
Obesity, Morbid, Obstetric Anesthesia Problems

Intervention / Treatment
-----------------
* Device: infrared transluminescent device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria > 18 years surgery that need double intravenous perfusion Exclusion Criteria: < 18 years body mass index< 35 refusal minor surgery that need only one intravenous access

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obese<br>Patients need two intravenous access with infra red | Device: infrared transluminescent device<br>* use of infra red for venous access for second intravenous access<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| success for second intravenous line using infra red | number of attempts | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time | time in second for second intravenous access | 1 day |
Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate the molecular mechanism underlying the erythroid response observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina.

Official Title
-----------------
Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Conditions
-----------------
Myelodysplasia, Myelofibrosis, Aplastic Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 and older Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia transfusion-dependent anemia undergoing chelation therapy with deferasirox or deferoxamine Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the molecular mechanism underlying the erythroid response | The primary outcome is to evaluate the molecular mechanism underlying the erythroid response (hemogoblin increase and reduction or elimination of trasfusion dependence) observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MDS, PMF, CMML, AA
A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation administered orally every 8 hours for 4 weeks.

Detailed Description
-----------------
Patients are randomly assigned to one of the four treatment groups as follows: Group 1: 10 patients receive saquinavir HGC. Group 2: 10 patients receive saquinavir SGC. Group 3: 30 patients receive saquinavir SGC at an intermediate dose. Group 4: 30 patients receive saquinavir SGC at the highest study dose. Upon completion of the initial 4 weeks, all patients may have the option to continue their originally-assigned therapy as monotherapy unless significant drug toxicity intervenes. If the analysis of the initial 4 week data identifies an optimal dose of saquinavir SGC, patients may have the option to change to this optimal dose in a treatment extension phase of the protocol. Patients in this extension phase may choose to remain on monotherapy unless they experience significant drug toxicity, their CD4 count or HIV-RNA levels return to baseline, until saquinavir is approved by the FDA or study termination, whichever comes first. NOTE: A washout >= 28 days is required for patients on antiretroviral therapy.

Official Title
-----------------
A Randomized, Parallel, Open-Label Study Comparing Saquinavir (Hard Gelatin Formulation, 600 Mg Tid) to Saquinavir Soft Gelatin Formulation [(400 Mg, 800 Mg, 1200 Mg) Tid} x 4 Weeks in HIV Infected Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Saquinavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: CD4 count of 100 to 500 cells/mm3. Greater than 20,000 HIV-RNA copies/ml. Exclusion Criteria Prior Medication: Excluded: Prior treatment with protease inhibitors. Required: Less than 8 weeks prior antiretroviral treatment (For at least 25% of patients). At least 8 weeks prior antiretroviral treatment (For at least 25% of patients).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Saquinavir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Administration Schedule, HIV Protease Inhibitors, Dosage Forms, Saquinavir, Anti-HIV Agents
Screening for Urinary Incontinence by Primary Care Providers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to: Assess the rate of screening for urinary incontinence (UI) in women by their primary care providers Identify the type of screening used by primary care providers Identify barriers to screening for UI Identify differences in screening rates between specialties Assess whether primary care providers view UI as a serious medical problem Assess the comfort level of primary care providers in the diagnosis and treatment of UI Identify primary care providers' preferred mode of learning more about UI

Detailed Description
-----------------
UI is a very common condition whose prevalence can be expected to increase dramatically in the coming decades. Treatment options are available to improve women's health and quality of life. However, inadequate communication between physicians and patients leads to decreased diagnosis and treatment. Past studies evaluating the use of screening by primary care providers, who act as gatekeepers in our healthcare system, clearly demonstrate that improvements must be made in the screening system. We propose a survey of local primary care providers to quantify screening rates for UI and identify barriers to successful screening. The information collected in this survey will allow us to identify methods such as targeted education opportunities and patient literature or questionnaires that will assist providers and their patients in initiating discussion and evaluation of UI.

Official Title
-----------------
Screening for Urinary Incontinence by Primary Care Providers

Conditions
-----------------
Urinary Incontinence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All primary care providers in the Greater Rochester metropolitan area, including: Primary care Medical Doctors (MD), Doctors of Osteopathy (DO), Primary care Nurse Practitioners (NP), and Physician Assistants (PA) Exclusion Criteria: Physicians in the Greater Rochester metropolitan area who are not primary care providers

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire |  | Response to mailing |
A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan

Study Overview
=================
Brief Summary
-----------------
A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Volunteers

Official Title
-----------------
A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Volunteers

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Cilnidipine/Valsartan
* Drug: Cilnidipine+Valsartan
* Drug: Cilnidipine/Valsartan
* Drug: Cilnidipine+Valsartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 20 and 40 Signed informed consent Exclusion Criteria: Has a history of hypersensitivity to IP ingredients Hypertension of hypotension

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cinidipine/Valsartan tablet<br>Cinidipine/Valsartan tablet | Drug: Cilnidipine/Valsartan<br>* Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle<br>Drug: Cilnidipine+Valsartan<br>* Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle<br>|
| Active Comparator: Cilnidipine+Valsartan<br>coadministration of cilinidipine and valsartan | Drug: Cilnidipine+Valsartan<br>* Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle<br>Drug: Cilnidipine/Valsartan<br>* Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUClast |  | 0 24hr | 
| Cmax |  | 0 24hr |
Hemodynamic Effects of Spironolactone in Patients With Heart Failure

Study Overview
=================
Brief Summary
-----------------
To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action. Randomized, two group placebo controlled, single blind study.

Official Title
-----------------
Hemodynamic Effects of Spironolactone in Patients With Heart Failure

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Drug: Spironolactone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CHF 21 - 80 years Serum creatinine < 2 mg/dL Serum potassium 2.7 - 4.5 mg/dL measured within past 4 weeks Exclusion Criteria: Less than 21 years Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Study patient will take 100mg tablet of Spironolactone | Drug: Spironolactone<br>* 100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Echocardiogram |  | 3 measurements 15 minutes apart before drug and 15 minutes for 2 hours after drug | 
| Measure of Kidney function and potassium levels |  | This will be taken before drug, two hours after and the following day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Congestive Heart Failure, Hemodynamics, Echocardiographs
Hostility and Coronary Risk--Role of Weak Vagal Function

Study Overview
=================
Brief Summary
-----------------
To determine whether deficient vagal antagonism of sympathetic nervous system (SNS) actions on the heart contributed to increased coronary heart disease risk in hostile persons.

Detailed Description
-----------------
DESIGN NARRATIVE: Sophisticated electrophysiologic monitoring approaches were used to: 1) show greater sensitivity in nonhostile young men to T-wave attenuation effects of isoproterenol infusion following vagal blockade; 2) show that vagal enhancement reduced and shortened the T-wave attenuation effects of isoproterenol infusion more in hostile young men; 3) evaluate these effects of vagal blockage and enhancement in middle-aged men and in young and middle-aged women; and 4) relate the T-wave effects in these studies to other measures of vagal tone and other biobehavioral mechanisms of coronary-prone behavior. Four studies were conducted in normal young and middle-aged men and women selected as high and low on hostility, evaluating vagal tone measures and effects of isoproterenol infusion on EKG T-wave and ST response after pretreatment with saline, neostigmine, and atropine. Demonstration that hostility was associated with deficient vagal anatagonism of SNS effects on the heart, especially in middle-aged as compared to younger persons, suggested that diminished vagal tone was one pathway whereby high hostility contributed to increased CHD risk. Clinical studies were then conducted to determine whether weaker vagal tone predicted increased myocardial ischemia and/or poorer outcomes in coronary heart disease patients. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |